V. Lehmensiek's Profile

Role	Title	Level	Year	L/R
🐬	Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes. J. Hess, D. Miko, A. Catic, V. Lehmensiek, D. Russell, Stefan H. E. Kaufmann	7	1998	7 🐬
🐜	The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS) 13 auth. J. Brettschneider, Anne Czerwoniak, M. Senel, Lubin Fang, J. Kassubek, E. Pinkhardt, F. Lauda, T. Kapfer, S. Jesse, V. Lehmensiek, ... A. Ludolph, M. Otto, H. Tumani	7	2010	7 🐜
🐜	IgG Antibodies against Measles, Rubella, and Varicella Zoster Virus Predict Conversion to Multiple Sclerosis in Clinically Isolated Syndrome 8 auth. J. Brettschneider, H. Tumani, U. Kiechle, R. Muche, G. Richards, V. Lehmensiek, ... A. Ludolph, M. Otto	6	2009	6 🐜
🐜	Neurofilament ELISA validation. 78 auth. A. Petzold, A. Altıntaş, L. Andreoni, A. Bartoš, A. Berthele, M. Blankenstein, L. Buée, M. Castellazzi, S. Cepok, M. Comabella, C. Constantinescu, F. Deisenhammer, G. Deniz, G. Erten, M. Espiño, ... E. Fainardi, D. Franciotta, M. Freedman, V. Giedraitis, N. Gilhus, G. Giovannoni, A. Głąbiński, P. Grieb, H. Hartung, B. Hemmer, S. Herukka, R. Hintzen, M. Ingelsson, Sam Jackson, Steve Jacobsen, Naghmeh Jafari, M. Jałosiński, S. Jarius, E. Kapaki, B. Kieseier, Marleen J. A. Koel-Simmelink, J. Kornhuber, J. Kuhle, J. Kurzepa, P. Lalive, L. Lannfelt, V. Lehmensiek, P. Lewczuk, P. Livrea, F. Marnetto, D. Martino, T. Menge, N. Norgren, Eva Papuć, G. Paraskevas, T. Pirttilä, C. Rajda, K. Rejdak, J. Říčný, D. Řípová, L. Rosengren, M. Ruggieri, S. Schraen, G. Shaw, C. Sindic, A. Siva, T. Stigbrand, I. Stonebridge, B. Topcular, M. Trojano, H. Tumani, H. Twaalfhoven, L. Vécsei, V. van Pesch, H. Vanderstichele, C. Vedeler, M. Verbeek, L. Villar, Robert Weissert, B. Wildemann, Cui Yang, Karen Yao, C. Teunissen	6	2010	6 🐜
🐜	Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF 23 auth. C. Warnke, M. Stettner, V. Lehmensiek, T. Dehmel, Anne K. Mausberg, G. von Geldern, R. Gold, T. Kümpfel, R. Hohlfeld, M. Mäurer, ... M. Stangel, V. Straeten, V. Limmroth, T. Weber, C. Kleinschnitz, M. Wattjes, A. Svenningsson, T. Olsson, H. Hartung, D. Hermsen, H. Tumani, O. Adams, B. Kieseier	6	2015	6 🐜
🦁	Cerebrospinal fluid proteome profile in multiple sclerosis 7 auth. V. Lehmensiek, S. Süssmuth, G. Tauscher, J. Brettschneider, S. Felk, F. Gillardon, ... H. Tumani	6	2007	6 🦁
🦁	Expression of mutant &agr;-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro V. Lehmensiek, Eva-Maria Tan, J. Schwarz, A. Storch	5	2002	5 🦁
🐜	CSF proteome analysis in clinically isolated syndrome (CIS): Candidate markers for conversion to definite multiple sclerosis 12 auth. Hayrettin Tumani, V. Lehmensiek, D. Rau, I. Guttmann, G. Tauscher, H. Mogel, ... C. Palm, V. Hirt, S. Suessmuth, I. Sapunova-Meier, A. Ludolph, J. Brettschneider	5	2009	5 🐜
🐜	Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS) 8 auth. J. Brettschneider, V. Lehmensiek, H. Mogel, M. Pfeifle, J. Dorst, C. Hendrich, ... A. Ludolph, H. Tumani	5	2010	5 🐜